Physician profile
Steve Karp
NPI 1831184787
$3,585.41
in general payments reported to CMS, 2019-2025
15 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $235 · 2021: $1,245 · 2022: $660 · 2023: $322 · 2024: $414 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $809.28 | 2019-2024 | Opdivo |
| Blue Earth Diagnostics | $699.49 | 2021 | |
| Janssen Biotech, INC. | $687.56 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Seagen INC. | $367.30 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $252.16 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.55 | 2019-2022 | |
| Genentech USA, INC. | $96.94 | 2019 | |
| Merck Sharp & Dohme LLC | $93.63 | 2019 | |
| Amgen INC. | $93.03 | 2020 | |
| Mirati Therapeutics, INC. | $92.48 | 2024 | Krazati |
| Incyte Corporation | $85.08 | 2022 | |
| Gilead Sciences, INC. | $81.90 | 2023 | Trodelvy |
| Siemens Medical Solutions USA, INC. | $27.89 | 2023 | Somatom Go.Top |
| Novartis Pharmaceuticals Corporation | $24.27 | 2024 | |
| Brainlab, INC. | $22.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Karp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.